|Bid||19.00 x 900|
|Ask||0.00 x 800|
|Day's Range||20.00 - 20.66|
|52 Week Range||16.65 - 57.22|
|Beta (5Y Monthly)||1.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Beam Therapeutics Inc (NASDAQ: BEAM) * Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO) * Kronos Bio Inc (NASDAQ: KRON) (IPOed Friday) * Larimar Therapeutics Inc (NASDAQ: LRMR) * Pacific Biosciences of California Inc (NASDAQ: PACB) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * Twist Bioscience Corp (NASDAQ: TWST)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 15) * ADC Therapeutics SA (NYSE: ADCT) * Alector Inc (NASDAQ: ALEC) * Artelo Biosciences Inc (NASDAQ: ARTL) * Aziyo Biologics Inc (NASDAQ: AZYO) * Codiak BioSciences Inc (NASDAQ: CDAK) (listed on Nasdaq Wednesday) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) * Dyne Therapeutics Inc (NASDAQ: DYN) * Pandion Therapeutics Inc (NASDAQ: PAND) * ProQR Therapeutics NV (NASDAQ: PRQR) * Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN) * Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP) (provided a strategic and corporate update) * Uniqure NV (NASDAQ: QURE)Stocks In Focus Zogenix Presents Data Showing Durability of Response For Seizure Drug Zogenix, Inc. (NASDAQ: ZGNX) released interim data from open-label extension trial, showing substantial seizure reductions were maintained when treated with Fintepla oral solution for up to two years. Post-hoc analysis showed number needed to treat to achieve a clinically meaningful response compared favorably to similar studies of other Dravet syndrome therapies, the company added.Fintepla was approved by the FDA for the treatment of seizures associated with Dravet syndrome in June.The data was presented at the Child Neurology Society and International Child Neurology Congress.The stock rose 7.03% to $21 in after-hours trading.Amarin Presents Positive Post-hoc Analyses of Vascepa Data Amarin Corporation plc (NASDAQ: AMRN) presented at the Transcatheter Cardiovascular Therapeutics Connect 2020 post hoc subgroup analyses of REDUCE-IT study, showing Vascepa compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events, or MACE, in patients with a history of percutaneous coronary intervention by 34% and 39%, respectively.Vascepa reduced key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 34%, it added.In after-hours trading, the stock added 3.96% to $5.25.Chembio Submits EUA Application For Rapid COVID Antigen Test Chembio Diagnostics Inc (NASDAQ: CEMI) announced the submission of an application for emergency use authorization to the FDA for the DPP SARS-CoV-2 Antigen test system, which has been designed to detect SARS-CoV-2 antigens in only 20 minutes.The stock gained 3.53% to $4.99 in after-hours trading.Orchard Gets European Medicines Agency Committee's Recommendation For Rare Inherited Disease Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) said the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending full, or standard, marketing authorization for Libmeldy, an investigational gene therapy for the treatment of metachromatic leukodystrophy, characterized by biallelic mutations in the ARSA gene.A final decision by the EC for Libmeldy is anticipated before the end of 2020, the company said.In premarket trading Friday, the stock was up 7.14% to $4.50.Galapagos' Osteoarthritis Drug Fails to Meet Primary, Secondary Endpoints In a Phase 2 Study Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) and Servier announced topline results from their ROCCELLA Phase 2 study of GLPG1972/S201086 in osteoarthritis patients, showing no signal of activity was observed.The study participants were treated with three different once-daily oral doses of the combo over 52 weeks of treatment period. The primary objective of the study was to show efficacy of in reducing cartilage loss of the central medial tibiofemoral compartment of the target knee via quantitative MRI.Galapagos shares were slipping 8.48% to $126.75 in premarket trading.Intersect ENT Expects Q3 Revenues to Exceed Expectation Intersect ENT Inc (NASDAQ: XENT) announced preliminary third-quarter revenues of $22.4 million to $22.8 million, ahead of the $21.37-million consensus estimate. As of Sept. 30, cash and marketable securities stood at $130 million."Our solid third quarter preliminary revenue reflects a continuation of increased sequential sinus surgery procedure demand leading to strong volumes of PROPEL, with notable year-on-year growth of PROPEL in the office setting," the company said.Based on current trends, the company projected fourth-quarter revenues to be 85-90% of the year-ago revenues, while analyst estimate revenues to be about 95% of 2019 fourth-quarter levels.Offerings Rocket Pharmaceuticals announced the secondary offering of 17.34 million shares of its Class A ordinary shares by selling shareholders in an underwritten public offering has been priced at $42 apiece.The offering is expected to close Oct. 20.On The Radar Clinical Readouts Rocket Pharma is scheduled to present at the European Society for Immunodeficiencies 2020 meeting an update on data from the Phase 1 portion of the Phase 1/2 clinical trial of RP-L201, lentiviral-mediated ex-vivo gene therapy, for leukocyte adhesion deficiency-I. The company will also present an e-poster consisting of preclinical study data on RP-L401 for infantile malignant osteopetrosis.IPOs Irvine, California-based Tarsus Pharmaceuticals, Inc., which is focused on developing therapies primarily for ophthalmic conditions, priced its upsized initial public offering, or IPO, of 5.5 million shares at $16 for raising gross proceeds of $88 million. The company had earlier estimated a price range of $15-$17. The shares are expected to begin trading on the Nasdaq under the ticker symbol TARS.Aligos Therapeutics, Inc., a South San Francisco, California-based clinical-stage biopharma currently focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, priced its IPO of 10 million shares at $15 per share, which is at the mid-point of the estimated price range of $14-$16. The company expects to raise gross proceeds of $150 million from the offering. The shares will likely begin trading on the Nasdaq under the ticker symbol ALGS.Houston, Texas-based Kiromic biopharma, Inc. priced its upsized IPO of 1.25 million shares at $12 apiece, which is the lower bound of the estimated price range of $12-$14. Gross proceeds from the offering is estimated at $15 million. The immuno-oncology company said its shares will begin trading on the Nasdaq under the ticker symbol KRPB.Cambridge in Massachusetts-based Praxis Precision Medicines Inc. priced its upsized IPO of 10 million shares at $19, above the estimated price range of $16-$18. The company, which translates genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, expects the shares to be listed on the Nasdaq under the ticker symbol PRAX. Gross proceeds from the offering are expected at $190 million.Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout * The Daily Biotech Pulse: Patent Award For Theratechnologies, Enzo Biochem's Q4, Codiak Debuts(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares in Zogenix (ZGNX) rallied 7% in Thursday’s after-hours trading after the company shared new data for Fintepla (fenfluramine) oral solution in Dravet syndrome at the Child Neurology Congress 2020.Dravet syndrome is a rare, highly refractory form of infant- and childhood-onset epilepsy marked by frequent and often prolonged seizures that are difficult to control with existing medications, significant cognitive and motor impairments, and a higher risk of sudden death.Efficacy was assessed as the reduction in monthly convulsive seizure frequency (MCSF) from core study baseline. Patients experienced a clinically meaningful and statistically significant reduction in MCSF over the entire treatment period of two years (-63%).“In addition to the significant convulsive seizure reductions seen in all three multi-national Phase 3 studies of FINTEPLA in Dravet syndrome, we are proud to collaborate with expert clinician investigators to show the durability of the clinically meaningful seizure reduction that FINTEPLA provided for patients treated for up to two years,” said Bradley S. Galer, Chief Medical Officer at Zogenix.Furthermore, new post-hoc data analysis demonstrated that for every two to three patients treated with Fintepla, one patient achieved ≥75% (profound) convulsive seizure reduction compared with placebo.“We believe these new data analyses further showcase the clinical value that FINTEPLA provides for many Dravet syndrome patients and their families” stated Galer.Shares in ZGNX have plunged over 60% year-to-date, but analysts have a cautiously optimistic Moderate Buy consensus on the stock’s outlook. That’s with an average analyst price target of $45- indicating shares can more than double from current levels.“We continue to believe in Fintepla’s long-term potential to be the standard of care for Dravet Syndrome, particularly following promising early launch indicators” comments Mizuho Securities analyst Difei Yang. She has a buy rating on Zogenix and $55 price target.She sees upside in ZGNX shares driven by Fintepla in Dravet, an area of high unmet medical need and from additional pipeline indications including Lennox–Gastaut syndrome; adding that the firm’s revenue estimates of $4.2mil/$45.7mil for 2020/2021 are achievable with potential upside. (See Zogenix stock analysis on TipRanks)Related News: Vertex Sinks 12% On Halt of VX-814 Development; Merrill Lynch Says Buy J&J Halts Covid-19 Vaccine Trial Due To ‘Unexplained Illness’ Amarin Pops 4% After-Hours On Positive PCI Data For Vascepa More recent articles from Smarter Analyst: * Intuitive Surgical Plunges 4% Despite 3Q Earnings Beat * Cars.com Soars 26% On Strong 3Q Sales Outlook, Analyst Upgrade * Marten Transport Sinks 8% After-Hours On 3Q Revenue Miss * Raytheon Scores $239M US Air Force Contract Modification